RBC Capital initiates IQVIA Holdings stock at Outperform on trial activity outlook
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil extends surge on wider Middle East conflict, Strait of Hormuz closure Gold dips, reverses course as stronger dollar weighs amid Iran conflict Gold price surge after Iran attack could fade, Pepperstone says Dollar surges to over five-week high on U.S.-Iran escalation; euro, sterling slip FLASH SALE (South Africa Philippines Nigeria) FLASH SALE RBC Capital initiates IQVIA Holdings stock at Outperform on trial activity outlook By Investing.com Analyst Ratings Published 03/03/2026, 02:48 AM RBC Capital initiates IQVIA Holdings stock at Outperform on trial activity outlook 0 IQV -2.54% Investing.com - RBC Capital initiated coverage on IQVIA Holdings Inc. (NYSE:IQV) with an Outperform rating and a price target of $221.00. The stock currently trades at $174.27, suggesting potential upside of 27% to the analyst’s target. According to InvestingPro analysis, the company appears undervalued based on its Fair Value assessment. Analyst Ryan Halsted cited data points suggesting an increase in clinical trial activity into 2026 as a key factor behind the rating. RBC Capital believes IQVIA is positioned to benefit from an inflection in the contract research organization market based on its data analytics capabilities built with over 64 petabytes of data and relationships with large pharmaceutical companies. The company, with a market capitalization of $29.25 billion, generated $16.31 billion in revenue over the last twelve months with growth of 5.87%. InvestingPro identifies IQVIA as a prominent player in the Life Sciences Tools & Services industry, with a comprehensive Pro Research Report available for deeper analysis. The firm views the company’s proprietary data as a critical differentiator as real world evidence gains adoption in trials. RBC Capital also noted the expanding role of artificial intelligence in life sciences as a factor supporting its outlook for the company. In other recent news, IQVIA Holdings Inc. ann...
Read full article at source